Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 16, 2025, titled "Zynext Ventures Invests in Feldan Therapeutics to Drive Innovation in Intracellular Drug Delivery".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences announced through a press release dated April 16, 2025, that Zynext Ventures (its corporate venture capital arm) has made an investment in Feldan Therapeutics. Feldan Therapeutics specializes in intracellular drug delivery technology, which involves getting therapeutic agents inside cells more effectively. This investment signals Zydus's continued push into cutting-edge biotech innovation through its venture arm rather than direct in-house R&D spend. The press release was shared with the stock exchange as a regulatory disclosure but does not specify deal size or financial terms.
This is a strategic investment through Zydus's VC arm and is unlikely to materially move the stock price in the short term. However, it reinforces Zydus's positioning in advanced drug delivery technology, which could create long-term value if Feldan's platform yields commercial products.